Transplantation and Cellular Therapy
Издатель: Elsevier · ISSN 2666-6367 · 97 статей
- Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes
- Predictors of Rehabilitation Utilization After CAR T-Cell Therapy
- Harnessing the Power of Two: High-Dose Stem Cell Haploidentical Transplant in Hematologic Malignancies: A Prospective Trial
- Safety and Outcomes of CD19 CAR-T Cell Therapy in Splenectomized Patients With B-Cell Lymphomas
- Clinical Impact of Discordant Minimal Residual Disease Assessment in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
- Integrated Analysis of Hematopoietic Changes Following Heterochronic Bone Marrow Transplantation Between Young and Aged Mice
- Cis-targeted IL-2 Mutein to Augment the Antitumor Activity of Engineered T Cells
- Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma
- Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival
- Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma
- Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia
- Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma
- Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Versus-Host Disease and Nonrelapse Mortality After Allogeneic Transplantation
- Absence of Pretransplant Peripheral Blasts is Favorable Factor in Allogeneic Stem Cell Transplantation for Advanced Acute Lymphoblastic Leukemia
- A longitudinal investigation of the financial impact of receiving chimeric antigen receptor t-cell therapy
- A Retrospective Study Evaluating the Efficacy of Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor with/without Idarubicin Followed by Second Allogeneic Stem Cell Transplant in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia/Myelodysplastic Syndrome Following First Allogeneic Stem Cell Transplant
- Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity
- International Survey and Next-Generation Sequencing-Based Indel Chimerism Detection of Human Leukocyte Antigens Loss in Relapsed Haploidentical and Mismatched Unrelated Donor Transplant Recipients
- Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD Status
- Discontinuing Ciprofloxacin Prophylaxis in Allogeneic Stem Cell Transplantation Does Not Result in Inferior Outcomes
- Feasibility of 8 Gy TBI-Busulfan-Fludarabine Conditioning With Post-Transplant Cyclophosphamide for Pediatric High-Risk or Relapsed Acute Lymphoblastic Leukemia
- High Predicted Thiotepa Exposure is Associated with Increased Risk of Thrombotic Microangiopathy and Non-Relapse Mortality in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation
- Overcoming Donor-Specific Anti-Human Leukocyte Antigen Antibodies With Desensitization in Adult Ex-Vivo T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation: A Real-World Analysis
- Haploidentical Hematopoietic Stem Cell Transplantation Drives Time-dependent premature T Cell Senescence: Recipient Microenvironment Modulates Donor T Cell Epigenetic Aging, Telomere Homeostasis and SASP Remodeling
- Association of a Digital Clinical Decision Support Platform With Early Outcomes After Pediatric Allogeneic Hematopoietic Cell Transplantation: A Three-Era Guideline Implementation Cohort Study
- The Role of Physical Therapy Across the Transplant Trajectory in Allogeneic Hematopoietic Stem Cell Transplantation, A Systematic Review and Clinical Framework
- Cytomegalovirus After Autologous Hematopoietic Cell Transplantation: Impact on Outcome and A Personalized Risk-Adapted Prevention Strategy
- Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
- Real-World Use of Maribavir for Refractory CMV Infection and Intolerance to Conventional Anti-CMV Agents After Allogeneic Hematopoietic Cell Transplantation
- Trends and Disparities in Chimeric Antigen Receptor T-Cell Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017 to 2022)